Hisun Pharmaceutical (600267.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 1.146 billion yuan, a year-on-year increase of 148.56%.

Zhitong Finance APP News, Hisun Pharmaceutical (600267.SH) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 6.521 billion yuan, a year-on-year decrease of 17.70%; net profit attributable to shareholders of the listed company was 1.146 billion yuan, a year-on-year increase of 148.56%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 982 million yuan, a year-on-year increase of 100.11%; basic earnings per share were 0.99 yuan.